A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

Bone Marrow Transplantation

Volumn 28, Issue 3, 2001, Pages 295-303

  Pecora, A L ^a   Stiff, P ^b   LeMaistre, C F ^c   Bayer, R ^b   Bachier, C ^c   Goldberg, S L ^a   Parthasarathy, M ^b   Jennis, A A ^a   Smith, A K ^d   Douville, J ^d   Chen, B ^b   Armstrong, R D ^d   Mandalam, R K ^d   Preti, R ^e  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c South Texas Cancer Institute   (United States)

^d Aastrom Biosciences Inc   (United States)

^e Progenitor Cell Therapy   (United States)

Author keywords

Ex vivo expansion; Low dose blood stem cells

Indexed keywords

CARBOPLATIN; CD14 ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GLYCOPHORIN A; GLYCOPROTEIN P 15095; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; APHERESIS; ARTICLE; BIOLOGICAL THERAPY; BLOOD AUTOTRANSFUSION; BLOOD CELL COUNT; BONE MARROW BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CULTURE; CELL LINEAGE; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; METHODOLOGY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAFETY; STEM CELL; STEM CELL TRANSPLANTATION; SYSTEM ANALYSIS; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CYTAPHERESIS; EQUIPMENT SAFETY; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; STROMAL CELLS; TREATMENT OUTCOME;

EID: 17944364269     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703137     Document Type: Article

References (39)

1. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematological recovery and cost
2. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
3. Granulocyte colony-stimulating factor 'mobilized' peripheral-blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy
4. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 malignant lymphoma
5. An analysis of engraftment kinetics as a function of the CD34 content of peripheral-blood progenitor cell collections in 692 patients after the administration of myeloblative chemotherapy
6. Factors that influence collection and engraftment of autologous peripheral-blood stem cells
7. - cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients
8. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
9. Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients
10. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation
11. + cell yields
12. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization
13. Gene-marking to trace origin of relapse after autologous bone marrow transplantation
14. Genetic markings shows that Ph+ cells present in autologous transplant CML contribute to relapse after ABMT in CML
15. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
16. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots following high-dose chemotherapy for breast cancer
17. Ex vivo perfusion culture expansion of tumor positive bone marrow from breast cancer patients results in passive purging during the culture period
18. Bioreactor expansion of human bone marrow: Comparison of unprocessed, density-separated, and CD34-enriched cells
19. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and cultured-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy
20. Clinical scale expansion of cryopreserved small volume whole bone marrow aspirates produces sufficient cells for clinical use
21. + cell determination by flow cytometry
22. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques
23. In vitro clonogenic growth of bone marrow micrometastasis from patients with breast cancer
24. Hematopoietic stem-cell harvesting and transplantation using G-CSF-primed BM: Comparison with unprimed BM and G-CSF-primed PBSC
25. Hematopoietic stromal microenvironment
26. + transduction
27. Disruption of bone marrow stromal cell function by etoposide
28. Treatment of marrow stromal monolayers reversibly alters hematopoiesis
29. Comparative analysis of hematopoietic growth factor release by stromal cells from normal donors for transplant patients
30. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma
31. Busulfan-induced chronic bone marrow failure: Changes in cortical bone, marrow stromal cells, and adherence cell colonies
32. Bone marrow stromal function from patients after bone marrow transplantation
33. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing dose of granulocyte colony-stimulating factor
34. Synergistic effects of thrombopoietin, SCF, and FLT3-L in ex vivo expansion cultures
35. + peripheral blood stem cells and in vitro expanded bone marrow cells
36. Management strategies for the hard-to-mobilize patient
37. Patient characteristics associated with successful mobilization in autografting of peripheral blood progenitor cells in malignant lymphoma
38. Peripheral blood stem cell mobilization for high-dose chemotherapy
39. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: Predictors and clinical outcomes